Literature DB >> 15295222

Elimination of racial differences in invasive pneumococcal disease in young children after introduction of the conjugate pneumococcal vaccine.

Thomas R Talbot1, Katherine A Poehling, Tina V Hartert, Patrick G Arbogast, Natasha B Halasa, Ed Mitchel, William Schaffner, Allen S Craig, Kathryn M Edwards, Marie R Griffin.   

Abstract

BACKGROUND: Racial differences in the epidemiology of invasive pneumococcal disease (IPD) have been widely recognized, but the impact of conjugate pneumococcal vaccine (PCV) introduction in 2000 on these differences has not been extensively studied.
METHODS: IPD episodes in 5 Tennessee counties from January 1995 through December 2002 were collected prospectively using the Centers for Disease Control and Prevention's Active Bacterial Core Surveillance system (ABCs). Trained nurses collected clinical data, and antibiotic susceptibility testing was performed on available isolates.
RESULTS: Before vaccine licensure, IPD rates were highest in children younger than 2 years and in blacks. The disparity in IPD rates between blacks and whites younger than 2 years of age substantially diminished after PCV introduction. In 1999, the IPD rate in black children younger than 2 years was 340.2 per 100,000, representing 176.5 more events per 100,000 than in white children (P < 0.001). In 2002, this rate had decreased 83% to 57.4 per 100,000, similar to the rate in white children (39.6 per 100,000; P = 0.31). Before vaccine licensure, a higher percentage of isolates from whites were antibiotic-nonsusceptible. In 2002, the proportion of antibiotic-nonsusceptible pneumococcal isolates was similar in whites and blacks of all ages for the first time during the study period (P > 0.05 for separate comparisons of penicillin, cephalosporin and erythromycin nonsusceptibility). These changes occurred despite a lower PCV vaccination coverage in Tennessee in blacks than in whites (31.2% versus 47.6%).
CONCLUSIONS: With conjugate pneumococcal vaccine introduction in Tennessee, racial differences in the incidence rates of IPD have largely been eliminated, particularly in young children.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15295222     DOI: 10.1097/01.inf.0000133046.60555.de

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  17 in total

1.  Socioeconomic and racial/ethnic disparities in the incidence of bacteremic pneumonia among US adults.

Authors:  Deron C Burton; Brendan Flannery; Nancy M Bennett; Monica M Farley; Ken Gershman; Lee H Harrison; Ruth Lynfield; Susan Petit; Arthur L Reingold; William Schaffner; Ann Thomas; Brian D Plikaytis; Charles E Rose; Cynthia G Whitney; Anne Schuchat
Journal:  Am J Public Health       Date:  2010-08-19       Impact factor: 9.308

2.  National hospitalization trends for pediatric pneumonia and associated complications.

Authors:  Grace E Lee; Scott A Lorch; Seth Sheffler-Collins; Matthew P Kronman; Samir S Shah
Journal:  Pediatrics       Date:  2010-07-19       Impact factor: 7.124

3.  Acceptance of pneumococcal vaccine under standing orders by race and ethnicity.

Authors:  Nicholas A Daniels; Susan Gouveia; Daniel Null; Ginny L Gildengorin; Carla A Winston
Journal:  J Natl Med Assoc       Date:  2006-07       Impact factor: 1.798

Review 4.  The impact of new vaccine introduction on immunization and health systems: a review of the published literature.

Authors:  Terri B Hyde; Holly Dentz; Susan A Wang; Helen E Burchett; Sandra Mounier-Jack; Carsten F Mantel
Journal:  Vaccine       Date:  2012-08-29       Impact factor: 3.641

5.  Persistent Sex Disparities in Invasive Pneumococcal Diseases in the Conjugate Vaccine Era.

Authors:  Annabelle de St Maurice; William Schaffner; Marie R Griffin; Natasha Halasa; Carlos G Grijalva
Journal:  J Infect Dis       Date:  2016-05-30       Impact factor: 5.226

6.  Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.

Authors:  Susanna Esposito; Susan Tansey; Allison Thompson; Ahmad Razmpour; John Liang; Thomas R Jones; Giuseppe Ferrera; Alessandro Maida; Gianni Bona; Caterina Sabatini; Lorenza Pugni; Emilio A Emini; William C Gruber; Daniel A Scott; Nicola Principi
Journal:  Clin Vaccine Immunol       Date:  2010-04-28

7.  Trends in antibiotic prescribing for adults in the United States--1995 to 2002.

Authors:  Christianne L Roumie; Natasha B Halasa; Carlos G Grijalva; Kathryn M Edwards; Yuwei Zhu; Robert S Dittus; Marie R Griffin
Journal:  J Gen Intern Med       Date:  2005-08       Impact factor: 5.128

8.  Decline in varicella-related ambulatory visits and hospitalizations in the United States since routine immunization against varicella.

Authors:  Samir S Shah; Sarah M Wood; Xiquan Luan; Adam J Ratner
Journal:  Pediatr Infect Dis J       Date:  2010-03       Impact factor: 2.129

9.  Pneumococcal conjugate vaccination in Canadian infants and children younger than five years of age: Recommendations and expected benefits.

Authors:  Carol A McClure; Michael W Ford; Jeff B Wilson; Jeff J Aramini
Journal:  Can J Infect Dis Med Microbiol       Date:  2006-01       Impact factor: 2.471

10.  Racial and Regional Differences in Rates of Invasive Pneumococcal Disease.

Authors:  Annabelle de St Maurice; Carlos G Grijalva; Christopher Fonnesbeck; William Schaffner; Natasha B Halasa
Journal:  Pediatrics       Date:  2015-10-12       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.